Toggle light / dark theme

Water, a molecule essential for life, exhibits unusual properties—referred to as anomalies—that define its behavior. Despite extensive study, many mysteries remain about the molecular mechanisms underlying these anomalies that make water unique. Deciphering and replicating this distinctive behavior across various temperature ranges remains a significant challenge for the scientific community.

Now, a study presents a new theoretical model capable of overcoming the limitations of previous methodologies to understand how water behaves in extreme conditions. The paper, featured on the cover of The Journal of Chemical Physics, is led by Giancarlo Franzese and Luis Enrique Coronas, from the Faculty of Physics and the Institute of Nanoscience and Nanotechnology of the University of Barcelona (IN2UB).

The study not only broadens our understanding of the physics of water, but also has implications for technology, biology and biomedicine, in particular for addressing the treatment of neurodegenerative diseases and the development of advanced biotechnologies.

Researchers from Baylor College of Medicine, Stanford University School of Medicine, and their collaborators have identified a novel compound called BHB-Phe, which is naturally produced by the body. Published in the journal Cell, their findings reveal that BHB-Phe regulates appetite and body weight by interacting with neurons in the brain.

Until now, BHB has been known as a compound produced by the liver to be used as fuel. However, in recent years, scientists have found that BHB increases in the body after fasting or exercise, prompting interest in investigating potential beneficial applications in obesity and diabetes.

Scientists have shown that in a direct cellular reprogramming scenario, neurons are produced almost exclusively by a rare subtype of multipotent cells. Their findings, they claim, change our understanding of reprogramming, but not everyone agrees [1].

Direct action

In the world of cellular reprogramming, the two most well-known realms are pluripotent reprogramming, in which somatic cells are thrown back all the way into pluripotency, and partial reprogramming, in which these cells are rejuvenated without making them lose their cellular identity.

Summary: Adolescents are known for making less optimal, noisy decisions, but a recent study reveals that these tendencies decrease with age and are linked to improvements in complex decision-making skills. Researchers found that decision noise, or variability in choices, mediates age-related gains in goal-directed behaviors and adaptability.

Adolescents may rely on less efficient strategies due to limited cognitive resources, which makes them more susceptible to emotional and motivational influences. These findings shed light on the computational mechanisms behind developmental shifts in decision-making and open avenues for understanding neurodevelopmental disorders.

Researchers from Johns Hopkins University have recently discovered several prominent biomarkers that allow for the early diagnosis of dementia and/or mild cognitive impairment (MCI). In a recently published article, evidence has been presented that patients with diabetes type 2 exhibited more changes to their brains than healthy controls, including the shrinking of certain brain areas. These changes occurred earlier in life, and some of the patients developed MCI sooner than others.

The Older Controls at Risk for Dementia (BIOCARD) study is a long-term trial which has been conducted for the past 27 years with the goal of determining how medical conditions and other factors might be impacting cognitive function and perhaps even affecting the biological age of the brain as a whole. BIOCARD was originally a National Institutes of Health initiative, which began in 1995 and later continued at Johns Hopkins University from 2015 to 2023. The cohort consisted of 185 participants, with an average age of 55 years and normal cognitive function.

The trial subjects received routine brain scans and cerebrospinal fluid (CSF) tests for 20 years, in order to measure changes in brain structures and levels of proteins associated with Alzheimer’s disease. Scientists have been increasingly using CSF to attempt to uncover early signs of neurodegenerative disease, since it is a minimally-invasive procedure which is inexpensive and widely available.

Summary: Male worms can activate two conflicting memories—mating and starvation—when encountering the same odor, but only one influences their behavior. A study conditioned worms to associate the smell with both positive (mating) and negative (starvation) experiences, revealing that mating associations overrode avoidance behavior.

This flexible memory processing highlights how the brain prioritizes rewards over punishment under certain conditions. The findings provide insights into memory-driven behavior and offer a model for studying maladaptive processes in disorders like PTSD.

Researchers led by the University of California, Irvine are the first to reveal how two neural circuits located in the brain’s retrosplenial cortex are directly linked to spatial navigation and memory storage. This discovery could lead to more precise medical treatments for Alzheimer’s disease and other cognitive disorders by allowing them to target pathway-specific neural circuits.

The study, published in Molecular Psychiatry, identified two types of RSC pathways, connected to different parts of the brain, each with its own pattern of inputs and functions.

“By demonstrating how specific circuits in the RSC contribute to different aspects of cognition, our findings provide an anatomical foundation for future studies and offer new insights into how we learn and remember the space around us,” said lead and co-corresponding author Xiangmin Xu, UC Irvine Chancellor’s Professor of anatomy and neurobiology and director of the campus’s Center for Neural Circuit Mapping.

Science Corporation, a biotech startup launched by a Neuralink cofounder, claims that it’s achieved a breakthrough in brain-computer interface technology that can help patients with severe vision loss.

In preliminary clinical trials, legally blind patients who had lost their central vision received the company’s retina implants, which restored their eyesight and even allowed them to read books and recognize faces, the startup announced last week.

“To my knowledge, this is the first time that restoration of the ability to fluently read has ever been definitively shown in blind patients,” CEO Max Hodak, who was president of Neuralink before founding Science Corp, said in a statement.